OGT SureSeq CLL + CNV V3 Panel

OGT has announced its updated SureSeq CLL + CNV V3 Panel, which further incorporates the company’s highly sensitive proprietary bait designs to offer more expansive coverage of disease-associated genes and enhanced CNV detection. The NGS panel now offers users more comprehensive variant detection to improve confidence in classification of CLL research samples to strengthen the understanding of CLL progression.

Harnessing direct input from leading clinical researchers in the field of CLL, the panel includes an expanded list of targeted genes alongside increases in probe density allowing for higher resolution and improved tumour content estimation. Changes in reference sample processing from external to internal reference DNA reduces inter-run variability and improves confidence in CNV calls. When compared to its predecessor, the updated panel — coupled with OGT’s complimentary NGS analysis software, Interpret — demonstrates a 38% increase in CNV detection, meaning users receive the optimal experience for profiling their samples.

Recent trials with the panel have demonstrated 100% detection of expected TP53 SNVs, with half of these estimated at between 1–5% VAF. Additionally, CNVs were confidently detected down to 20% tumour content with a 99% concordance with FISH testing.

The robust technical support provided by OGT makes the panel accessible to users with varying levels of expertise in molecular techniques. Additionally, the integration with bioinformatics software simplifies the data analysis process, providing clear and actionable results.

The product allows researchers to make informed decisions regarding their samples, with comprehensive variant detection and reassurance in their sample/disease classification, which is key to furthering our understanding of CLL progression. The addition of OGT’s Interpret software means users will be able to easily analyse their NGS data without the need for additional bioinformatic resources, maximising their efficiency.